Drugs that improve insulin sensitivity and glucose homeostasis are therefore of considerable interest in the context of NASH, some of which are already being considered as possible treatments for NASH (e.g. PPAR agonists)28. The gene discussed is PPARA; the disease is metabolic dysfunction-associated steatohepatitis.